Relapsing-remitting MS is the most common form, accounting for about 85% of all MS diagnoses. It is characterized by unpredictable relapses or exacerbations of symptoms or by the appearance of new symptoms followed by periods of remission. During periods of remission, symptoms may improve or even disappear. 5, 15 
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The September 2013 monograph topics are trametinib, simeprevir, paroxetine mesylate, and empagliflozin. The DUE/MUE is on aripiprazole.
Generic Name:
Dimethyl fumarate (BG-12) delayed-release capsules Proprietary Name: Tecfidera (Biogen Idec)
Approval Rating: 1S
Therapeutic Class: Immunomodulators
Similar Drugs: None
Sound-or Look-Alike Names: Dimethylglycine
INDICATIONS
Dimethyl fumarate is approved for the treatment of relapsing forms of multiple sclerosis (MS). 1, 2 Other oral therapies for the treatment of MS include teriflunomide (Aubagio) , approved for the treatment of patients with relapsing forms of MS, and fingolimod (Gilenya) , approved for the treatment of patients with relapsing forms of MS to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability. 3, 4 MS is a chronic autoimmune, inflammatory neurological disease that involves the myelin and axons in the central nervous system (CNS) . No drug has been proven to cure MS, but many drugs (eg, alemtuzumab, beta-interferons, cladribine, daclizumab, dalfampridine, fingolimod, glatiramer acetate, laquinimod, mitoxantrone, natalizumab, ocrelizumab, teriflunomide) with different pharmacologic effects have been used to help decrease symptoms and the frequency of exacerbations. [5] [6] [7] [8] [9] [10] [11] [12] [13] The ideal drug would decrease disease symptoms, decrease the frequency of exacerbations, slow or stop the progression of the disease, reverse pre-existing neurological damage, and improve the patient's quality of life. 10, 14 The course of MS is variable and unpredictable; MS is grouped into the following 4 major categories based on the course of the disease. 5, 15 these patients, the severity of the disease worsens over time. These patients may or may not experience periods of remission or decreased severity of symptoms. 5, 15 
Primary Progressive Multiple Sclerosis
Patients with primary progressive MS have a gradual worsening of symptoms throughout the course of the disease; the primary progressive form accounts for 10% to 15% of MS diagnoses. These patients do not experience remissions but may experience periods during which their symptoms do not continue to worsen. 5, 15 
Progressive Relapsing Multiple Sclerosis
Progressive relapsing is the least common form of MS and is characterized by disease that progresses from the beginning, with periods of worsening symptoms (exacerbations) and no periods of remission. 5, 15 
CLINICAL PHARMACOLOGY
Dimethyl fumarate is a fumaric acid ester. Its active metabolite is monomethyl fumarate. The exact mechanism of action of dimethyl fumarate is unknown. The drug and its metabolite are thought to work by activation of the nuclear factor (erythroidderived 2)-like (Nrf2) pathway, which is involved in the cellular response to oxidative stress. 1, 16 Protection of the neuron from oxidative metabolic stress may be provided by increased levels of antioxidant proteins. In addition, dimethyl fumarate may have antiinflammatory effects because of its blockade of nuclear factor kappa-B and its ability to prevent release of proinflammatory cytokines, lymphocyte activation, and differentiation of antigen-presenting cells. 9, [16] [17] [18] [19] [20] [21] [22] See Table 1 for a comparison of pharmacologic effects of the various drugs used for the treatment of MS.
PHARMACOKINETICS
Dimethyl fumarate is available as a delayed-release capsule. Once released from the capsule, the drug undergoes rapid hydrolysis to its active metabolite, monomethyl fumarate. Because the conversion occurs quickly and before systemic circulation, dimethyl fumarate is not detectable in quantifiable amounts in plasma, and all available pharmacokinetic information is related to monomethyl fumarate. 1 Table 1 . FDA-approved therapies for relapsing multiple sclerosis with corresponding mechanism of action and pharmacologic category 1, 3, 4, 11, [40] [41] [42] The median time to peak plasma concentration following oral administration of the delayed-release capsule is 2 to 2.5 hours. Changes in peak plasma concentrations and area under the curve (AUC) between 120 and 360 mg are approximately dose proportional. The mean peak plasma concentration of monomethyl fumarate in patients with MS taking dimethyl fumarate 240 mg twice daily with food is 1.87 mg/L, and the AUC is 8.2 mg•h/L. 1 Administration with a high-fat, high-caloric meal does not affect the AUC of monomethyl fumarate, but it does decrease its peak plasma concentration by 40%. Peak plasma concentration is delayed by 3.5 hours (from 2 to 5.5 hours). However, administration with food decreases the incidence of flushing by 25%. 1 Monomethyl fumarate is metabolized by the tricarboxylic acid cycle to carbon dioxide, fumaric acid, citric acid, and glucose. The cytochrome P450 (CYP-450) system is not involved in the metabolism of dimethyl fumarate or monomethyl fumarate. Elimination as carbon dioxide is the main route of elimination (approximately 60% of the dose). Renal elimination accounts for 16% of the dose, and fecal elimination accounts for 1% of the dose. 1 The Clinical effects appeared to be maintained for at least 1 year. Comments: The highest dimethyl fumarate dosage (240 mg 3 times daily) appeared to be well tolerated and produced better clinical outcomes than placebo. A subgroup analysis of this study population found that the 240 mg 3 times daily dosage was effective, based on a reduction in number of new Gd1 lesions from weeks 12 to 24 across various subgroups tested. The incidence of new Gd1 lesions compared with placebo was reduced by 74% in patients with an Expanded Disability Status Scale score of 2.5 or less and by 63% in those with a score greater than 2.5; by 80% in those with no pre-existing Gd1 lesions and by 55% in those with more than 1 pre-existing Gd1 lesion; by 49% in those younger than 40 years and by 89% in those 40 years or older; by 81% in female patients; and by 81% in those with a disease duration of 6 years or less and by 54% in those with a disease duration of longer than 6 years. 24 Another subgroup analysis retrospectively evaluated the magnetic resonance imaging (MRI) scans from this study. The percentage of Gd1 lesions that evolved to T1-hypointense lesions was 34% lower with dimethyl fumarate treatment than with placebo: 29% with dimethyl fumarate and 44% with placebo, with an odds ratio of 0.51 (95% confidence interval [CI], 0.43 to 0.61; P , .001). 25 Limitations: The study was powered to evaluate various dosages of dimethyl fumarate but not powered to evaluate the impact of the drug on the frequency of relapses.
Reference: Gold R, et al, 2012 (DEFINE study) [26] [27] [28] [29] [30] Study Design: Randomized (1:1:1), placebo-controlled, multicenter, phase 3 study Study Funding: Biogen Idec Patients: 1,237 adults with relapsing-remitting MS from the European Union, United States, Canada, and other countries were enrolled; 1,234 received at least 1 dose of the study drug (intent-to-treat cohort). Approximately 40% of patients had previously been treated with an approved therapy for relapsing-remitting MS. The proportion of patients completing the study was similar in both the placebo and dimethyl fumarate groups (78% in the placebo group and 77% in the dimethyl fumarate group). The mean duration of study participation was 83.9 weeks in all groups. Intervention: Oral administration of dimethyl fumarate 240 mg twice daily, dimethyl fumarate 240 mg 3 times daily, or placebo for 2 years. All patients were eligible to switch to an alternative therapy for MS if they had completed 48 weeks of study treatment and had 1 or more confirmed relapse after 24 weeks. Patients could also switch at any time if they had confirmed progression of disability. If a patient was switched to an alternative therapy, all data from before the switch were used for analysis of the clinical endpoints.
Results: Primary Endpoint(s):
Proportion of relapsing patients at 2 years in the intent-to-treat cohort: daily versus placebo (HR, 0.52; 95% CI, 0.5 to 0.67; P 5 .01). Disability progression risk was lower with both dosages of dimethyl fumarate compared with placebo: 38% reduction (HR, 0.63; 95% CI, 0.44 to 0.87; P 5 .005) with dimethyl fumarate twice daily and 34% reduction (HR, 0.66; 95% CI, 0.48 to 0.92; P 5 .01) with dimethyl fumarate 3 times daily. The estimated proportion with progression of disability was 27% with placebo, 16% with twice-daily dimethyl fumarate, and 18% with 3-times-daily dimethyl fumarate. MRI analysis showed reduced brain atrophy and lesion volume with dimethyl fumarate therapy from 6 months to 2 years.
Percentage of patients who switched therapy was low in all groups (13% in the placebo group, 6% in the dimethyl fumarate twice-daily group, and 5% in the dimethyl fumarate 3-times-daily group). Comments: Dimethyl fumarate is more effective than placebo in decreasing the relapse rate in patients with relapsing-remitting MS over 2 years. The incidences of new Gd1 lesions and disability progression are decreased with dimethyl fumarate therapy. All sensitivity analyses were consistent with those found in the primary efficacy analysis. Both dosages of dimethyl fumarate produced improvements in patients' reported health-related quality of life compared with placebo. 29 A subgroup analysis of this study population found that both dosages had a consistent effect on relapse and disability parameters compared with placebo. The HR for the risk of relapse over 2 years was 0.52 (95% CI, 0.38 to 0.71) with dimethyl fumarate twice daily and 0.51 (95% CI, 0.37 to 0.7) with dimethyl fumarate 3 times daily in patients who had 1 or fewer relapses in the year prior to study entry. In the group of patients who experienced 2 or more relapses during the year prior to study entry, the HR was 0.51 (95% CI, 0.34 to 0.77) with twice-daily dosing and 0.49 (95% CI, 0.32 to 0.74) with 3-timesdaily dosing. 31 Another subgroup analysis found that the proportion of disease-free patients over 2 years based on clinical parameters was 63% with dimethyl fumarate twice daily, 59% with dimethyl fumarate 3 times daily, and 39% with placebo (P , .001); based on radiologic findings, the proportion of disease-free patients over 2 years was 45%, 39%, and 27% (P , .05), respectively. The proportion of disease-free patients using a combination of clinical and radiologic findings was 28% with dimethyl fumarate twice daily, 26% with dimethyl fumarate 3 times daily, and 15% with placebo (P , .05). 32 Limitations: Most of the subgroup analyses have been published only as meeting abstracts or posters. .001) , and by 41% with glatiramer acetate (P , .002) compared with placebo. Comments: Dimethyl fumarate is more effective than placebo in decreasing the relapse rate in patients with relapsing-remitting MS over 2 years. The incidence of new Gd1 lesions was also decreased with dimethyl fumarate therapy. Both dosages of dimethyl fumarate produced similar improvements and appear more effective on these parameters than glatiramer acetate therapy. Limitations: The study was not powered for a direct comparison of glatiramer acetate and dimethyl fumarate. Instead, the glatiramer acetate group is an active comparator, but all statistical testing was done against placebo.
There are no head-to-head comparisons between dimethyl fumarate and either fingolimod or teriflunomide.
CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS Contraindications
There are no contraindications. 1
Warnings and Precautions
Lymphopenia may occur during dimethyl fumarate therapy. Mean lymphocyte counts decreased by approximately 30% during the first year of therapy in clinical trials and then remained stable. When dimethyl fumarate therapy was discontinued, mean lymphocyte count increased within 4 weeks but did not return to baseline. The incidence of lymphocyte counts less than 0.5 3 10 9 /L was 6% in dimethyl fumarate-treated patients and less than 1% in placebo-treated patients. However, the incidence of infections (60% vs 58%, respectively) and serious infections (2% vs 2%, respectively) was similar in both groups, and no cases of serious infections occurred in patients with lymphocyte counts less than 0.8 3 10 9 /L. Routine complete blood cell (CBC) counts should be performed throughout therapy. Withholding dimethyl fumarate therapy should be considered if the patient develops a serious infection. 1 Flushing (eg, warmth, redness, itching, and/or burning sensation) may occur with dimethyl fumarate therapy. Flushing occurred in 40% of dimethyl fumarate-treated patients and generally began soon after therapy initiation; it was most commonly classified as mild to moderate in severity and improved over time. Administration with food decreased the incidence of flushing in some patients. Flushing prompted discontinuation of therapy in 3% of patients and was reported to be serious and required hospitalization in less than 1%. 1 Dimethyl fumarate is classified in Pregnancy Category C; there are no adequate and well-controlled studies in pregnant women. Animal studies found problems with offspring survival, growth, sexual maturation, and neurobehavioral functions. If a pregnancy occurs during treatment with dimethyl fumarate therapy, the patient should be encouraged to enroll in the Tecfidera Pregnancy Registry. 1 It is not known whether dimethyl fumarate is excreted in human milk. 1 Safety and effectiveness in pediatric patients have not been established. 1 A postmarketing study in pediatric patients 10 to 17 years of age is required by the US Food and Drug Administration (FDA). 2 See Table 2 for a comparison of contraindications, warnings, and precautions associated with the approved oral MS drugs.
ADVERSE REACTIONS
The most common adverse reactions associated with dimethyl fumarate therapy (frequency of at least 10% and at least a 2% higher incidence than placebo) include flushing, abdominal pain, diarrhea, and nausea. 1, 27, 36 Flushing and GI reactions (abdominal pain, diarrhea, and nausea) occur more frequently at initiation of therapy and may decrease over time. 1, 27, 36 The most common adverse reactions reported with dimethyl fumarate therapy are summarized in Table 3 .
Flushing generally occurred within 30 minutes of drug administration, subsided within 90 minutes, and decreased with continued therapy. 23, 37 Pretreatment with aspirin can decrease the incidence and severity of flushing, but this method is not mentioned in the product labeling. 1, 37 Instead, product labeling recommends administration with food. 1 Elevations in hepatic transaminases may occur, generally within the first 6 months of therapy, and most patients had elevations of less than 3 times the upper limit of normal. Discontinuation because of The incidence of infections was similar in the dimethyl fumarate-and placebo-treated patients in the DEFINE and the CONFIRM studies. 30, 36 The incidence of infection in the DEFINE study was 65% in the placebo group, 64% in the twice-daily dimethyl fumarate group, and 68% in the 3-times-daily dimethyl fumarate group. The most common infections were nasopharyngitis, upper respiratory tract infection, urinary tract infection, and influenza. 30 The incidence of infection in the CONFIRM study was 50% in the placebo group, 65% in the dimethyl fumarate groups, and 50% in the glatiramer acetate group. The most common infections were nasopharyngitis, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, and gastroenteritis. 36 The incidence of renal adverse events was similar among treatment groups (21% with placebo, 22% with twice-daily dimethyl fumarate, and 25% with 3times-daily dimethyl fumarate); there were no cases of renal failure in the DEFINE study, but there was a difference in the incidence of proteinuria. 30 Proteinuria occurred in 8% of placebo-treated patients, 9% of patients receiving twice-daily dimethyl fumarate, and 12% of patients receiving 3-times-daily dimethyl fumarate. Proteinuria was classified as mild and reversible and did not result in discontinuation of treatment.
See Table 4 for a comparison of adverse reactions reported in the product labeling for the approved oral MS drugs. 
DRUG INTERACTIONS
No drug-drug interactions have been identified. 1 Administration of aspirin 30 minutes before oral administration of dimethyl fumarate had no effect on the pharmacokinetics of monomethyl fumarate. 1 See Table 5 for a comparison of the drug-drug interactions reported for the approved oral MS drugs.
RECOMMENDED MONITORING
Patients should be monitored for improvement in symptoms and frequency and severity of relapses prior to and after starting dimethyl fumarate therapy.
CBC counts should be measured at baseline (or at least within the last 6 months) and at least annually during therapy. Additional CBC counts should be obtained if clinically indicated. 1 See Table 6 for a comparison of recommended monitoring for oral MS drugs.
DOSING
The recommended starting dosage of dimethyl fumarate is 120 mg orally twice a day for 7 days. The dosage is then increased to the recommended maintenance dosage of 240 mg orally twice a day. 1 Table 5 . Drug-drug interactions for the approved oral multiple sclerosis drugs 1, 3, 4 Drug Table 7 for a comparison of dosing recommendations for the approved oral MS drugs.
PRODUCT AVAILABILITY
The new drug application for dimethyl fumarate was submitted to the FDA in February 2012. 38 Dimethyl fumarate was approved by the FDA in March 2013. 1, 2 Tecfidera is available as a hard gelatin delayedrelease capsule containing 120 or 240 mg of dimethyl fumarate. Each capsule contains dimethyl fumarate plus the following inactive ingredients: microcrystalline cellulose, silicified microcrystalline cellulose, croscarmellose sodium, talc, silica colloidal silicon dioxide, magnesium stearate, triethyl citrate, and polysorbate 80. The capsule shell contains gelatin, titanium dioxide, FD&C Blue No. 1, methacrylic acid copolymer type A, methacrylic acid copolymer dispersion, simethicone, sodium lauryl sulphate, brilliant blue FCF, yellow iron oxide, and black iron oxide. 1 The 120 mg capsule is available in a 7-day bottle containing 14 capsules. The 240 mg capsule is available in a 30-day bottle containing 60 capsules. Both strengths are available in a 30-day starter pack containing a 7-day bottle of 120 mg capsules and a 23-day bottle of 240 mg capsules. 1 Dimethyl fumarate should be stored at 15°C to 30°C (59°F to 86°F). The capsules should be stored in the original container and protected from light. Once the bottle is opened, its contents should be discarded after 90 days. 1 
DRUG SAFETY/RISK EVALUATION AND MITIGATION STRATEGY (REMS)
No REMS is required for dimethyl fumarate or teriflunomide, whereas a REMS program is required for fingolimod. 2, 3, 39 Postmarketing requirements include an evaluation of the in vitro receptor binding of dimethyl fumarate and its metabolite with various receptors; assessment of abuse potential with animals trained to discriminate the known drug of abuse from saline; juvenile rat toxicology study to model its potential effects in children; and a large, long-term, prospective observational study in adult patients with relapsing MS to determine the nature and incidence of various infections, malignancies, and serious adverse reactions. 2 
CONCLUSION
None of the drugs used for the treatment of MS are ideal. All drugs used in the treatment of MS have unique problems, but some have resulted in improvement in symptoms and decreased frequency of exacerbations. Dimethyl fumarate is another useful oral agent for the treatment of relapsing-remitting MS. Available data from phase 3 studies indicate that dimethyl fumarate is useful in decreasing the number of new lesions and the frequency of relapses. The headto-head comparison of oral dimethyl fumarate and subcutaneous glatiramer acetate showed that both dimethyl fumarate and glatiramer acetate were more effective than placebo, whereas dimethyl fumarate monotherapy was more effective than glatiramer acetate monotherapy for the treatment of patients with relapsing-remitting MS. There are no comparisons of dimethyl fumarate with other oral drugs (fingolimod or teriflunomide) used for the treatment of relapsingremitting MS. The key differences among the oral agents are the warnings, incidences of various adverse reactions, and dosing frequency associated with each drug. The key dimethyl fumarate warnings are regarding lymphopenia and flushing; fingolimod carries cardiovascular warnings (first-dose monitoring is required) and teriflunomide has been associated with hepatotoxicity and teratogenic effects. The most common adverse reactions reported with fingolimod include headache, influenza, diarrhea, back pain, liver transaminase elevation, and cough; teriflunomide adverse reactions include ALT elevation, alopecia, diarrhea, influenza, nausea, and paresthesia; and dimethyl fumarate adverse reactions include flushing, 
